Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.40 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643187 | 0.86 | DHFR (0.47) | DHFRALDH1A1CYP2D6ATMDCPS | |
| SCHEMBL3639875 | 0.85 | DHFR (0.55) | DHFRCYP2D6DCPS | |
| Hydrochloric Acid SCHEMBL3644393 | 0.84 | DHFR (0.46) | DHFRALDH1A1CYP2D6ATMDCPS | |
| SCHEMBL4194702 | 0.82 | MPO (0.41) | DHFRDCPS | |
| SCHEMBL1154650 | 0.81 | DHFR (0.57) | DHFRHSP90AB1DCPS | |
| SCHEMBL28725370 | 0.77 | DHFR (0.46) | DHFRSMN1; SMN2HSP90AB1ALDH1A1ADCY10 | |
| SCHEMBL4218504 | 0.73 | HSP90AB1 (0.53) | DHFRSMN1; SMN2HSP90AB1ALDH1A1CYP2D6 | |
| SCHEMBL5354603 | 0.72 | HSP90AB1 (0.51) | DHFRHSP90AB1 | |
| SCHEMBL2606210 | 0.71 | DHFR (0.76) | DHFRDCPS | |
| SCHEMBL12495806 | 0.71 | SMN1; SMN2 (0.63) | DHFRSMN1; SMN2HSP90AB1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-02-19 | — | — | US | claimed |
| EP-1963284-A1 | NOVEL QUINAZOLINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NeuroSearch A/S (DK) | 2008-09-03 | — | — | EP | claimed |
| WO-2007065913-A1 | NOVEL QUINAZOLINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-02-19 | — | — | US | disclosed |
| EP-1963284-A1 | NOVEL QUINAZOLINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NeuroSearch A/S (DK) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065913-A1 | NOVEL QUINAZOLINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | KCNN2, KCNN3, KCNN1 | DHFR 2754/4885SMN1; SMN2 2955/4885HSP90AB1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.